Patients with non-small cell lung cancer and the TT genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.